MedPath

Selective Sentinella Lymph Node Biopsy With Indocyanine Green in Patients With Breast Cancer

Recruiting
Conditions
Breast Cancer
Registration Number
NCT06378944
Lead Sponsor
Omphis Foundation
Brief Summary

The current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. The objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.

Detailed Description

In the operating room 1 ml of indocyaninge grenn will be injectec periareolar . After 5 minutes the lymph node will be detected and extracted. The comparison between the lymph nodes detected with Technetium 99 and indocyanine green will be analysed.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
15000
Inclusion Criteria
  • Patients >18 years of age with breast cancer who are candidates for sentinel lymph node detection will be included.
  • N0 patients or patients who have undergone target axillary detection with good response
Exclusion Criteria
  • Lymphadenectomy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Number of Sentinel lymph node detected. Scale of numberspatients included from 1 January of 2024 til January 1 2029

Number of lymph node detected with Indocyanine green and number of lymph node detected iwth techetium 99. Scale of numbers

Secondary Outcome Measures
NameTimeMethod
Number of possitive lymph nodespatients included from 1 January of 2024 til January 1 2029

assess whether there are differences in affected lymph nodes detected with indocyanine green or technetium 99 Number of possitive lymph nodes iwh indocyanine green and with technetium 99

surgery time in minutespatients included from 1 January of 2024 til January 1 2029

Time in minutes from skin incision to lymp node removal.

Trial Locations

Locations (1)

Sandra Lopez Gordo

🇪🇸

Cerdanyola Del Valles, Barcelona, Spain

© Copyright 2025. All Rights Reserved by MedPath